⚠️ This AI-generated report synthesizes publicly available information. AI can make mistakes. Please double check information in this report.
Recursion Pharmaceuticals, Inc.
Healthcare | Biotechnology
⚡ Executive Summary
📊 The Bottom Line
Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging technology for drug discovery. While the company demonstrates innovative potential through its AI-driven platform and strategic collaborations, it currently faces significant losses and a long path to profitability, typical for its stage.
⚖️ Risk vs Reward
At US$3.25, RXRX trades significantly below its average analyst target of US$6.71, suggesting potential upside. However, as a pre-profitability biotech, its valuation is highly sensitive to clinical trial outcomes and cash burn. The risk-reward profile is skewed towards higher risk due to the inherent uncertainties of drug development.
🚀 Why RXRX Could Soar
- • Successful progression of lead drug candidates (e.g., REC-4881, REC-617) through clinical trials could trigger substantial value inflection.
- • New strategic partnerships with major pharmaceutical companies could provide significant non-dilutive funding and validation for its AI-driven platform.
- • Demonstrated efficacy of its Recursion OS platform in accelerating drug discovery could attract further investment and expand pipeline efficiency.
⚠️ What Could Go Wrong
- • Clinical trial failures for any of its pipeline drugs would severely impact investor confidence and future revenue potential.
- • High cash burn rate (-US$371.8M operating cash flow) necessitates continuous financing, risking further share dilution or debt accumulation.
- • Intense competition in AI-driven drug discovery could lead to rapid obsolescence of its technology or failure to secure market share for future therapies.
🏢 Company Overview
💰 How RXRX Makes Money
- • Recursion Pharmaceuticals is a clinical-stage biotechnology company focused on decoding biology and chemistry to industrialize drug discovery.
- • It leverages a technology platform, known as Recursion OS, integrating innovations across biology, chemistry, automation, data science, and engineering to identify and develop new therapies.
- • The company primarily generates revenue through collaborations and agreements with major pharmaceutical partners like Roche & Genentech, Sanofi, Bayer AG, Tempus, and Takeda.
- • Its pipeline includes drug candidates in various clinical trial phases for conditions such as familial adenomatous polyposis, advanced solid tumors, and relapsed or refractory B-cell malignancies.
Revenue Breakdown
Collaboration Revenue
100%
Revenue derived from strategic alliances and partnerships for drug discovery and development.
🎯 WHY THIS MATTERS
The company's revenue model, heavily reliant on collaborations, provides critical funding and external validation for its technology platform. This strategy mitigates some of the financial risks associated with the capital-intensive nature of drug development, although direct product sales are still years away.
⭐ Competitive Advantage: What Makes RXRX Special
1. AI-Driven Drug Discovery Platform
Recursion utilizes a sophisticated AI/ML-powered platform, Recursion OS, to accelerate the identification of novel drug candidates and understand complex biological interactions. This approach can potentially reduce the time and cost associated with traditional drug discovery, increasing the probability of success in bringing new therapies to market.
2. Diverse Clinical Pipeline
The company maintains a pipeline of drug candidates targeting various diseases, including oncology and rare genetic disorders. This diversified approach spreads the risk inherent in clinical development and offers multiple avenues for potential future revenue, reducing reliance on the success of a single program.
3. Strategic Pharmaceutical Collaborations
Recursion has established partnerships with leading pharmaceutical companies such as Roche & Genentech and Sanofi. These collaborations provide access to significant resources, expertise, and potential milestone payments, validating its technology and offering pathways for late-stage development and commercialization.
🎯 WHY THIS MATTERS
Recursion's core strength lies in its innovative, technology-driven approach to drug discovery, which aims to bring efficiency and scale to a historically slow and expensive process. Coupled with a diverse pipeline and strategic partnerships, these advantages position the company to potentially disrupt the biotechnology landscape and deliver multiple new therapies over the long term, assuming clinical success.
👔 Who's Running The Show
Najat Khan
CEO, President & Director
Najat Khan, 40, leads Recursion as CEO, President & Director. With a background in science, she spearheads the company's mission to industrialize drug discovery through technological innovation. Her leadership is crucial in navigating the complex landscape of clinical development and leveraging the firm's AI platform for strategic growth and pipeline advancement.
⚔️ What's The Competition
The biotechnology industry, particularly the segment focused on AI-driven drug discovery, is highly competitive. Recursion faces competition from traditional pharmaceutical companies with extensive R&D capabilities, as well as emerging biotech firms also utilizing advanced computational methods. Success hinges on the ability to demonstrate superior efficacy and safety in clinical trials, coupled with efficient drug development.
📊 Market Context
- Total Addressable Market - The global drug discovery market is projected to reach over US$100B by 2030, driven by an aging population and advancements in personalized medicine.
- Key Trend - The most important trend is the increasing adoption of artificial intelligence and machine learning to accelerate drug target identification and lead optimization.
📊 Valuation & Analysis
📈 Wall Street Summary
Analyst Rating Distribution - 5 Hold, 1 Buy, 2 Strong Buy
5
1
2
12-Month Price Target Range
Low Target
US$3
-8%
Average Target
US$7
+106%
High Target
US$11
+238%
Closing: US$3.25 (20 Mar 2026)
🚀 The Bull Case - Upside to US$11
1. Positive Clinical Trial Readouts
Medium Probability
Successful results from ongoing Phase 1/2 trials for REC-4881 or REC-617 could significantly de-risk the pipeline, attracting more capital and partnership opportunities, potentially doubling the company's market capitalization.
2. Expansion of AI Platform Capabilities
High Probability
Further enhancements and validation of the Recursion OS platform, leading to new drug target discoveries or accelerated preclinical development, could position the company as a leader in AI-driven drug discovery, boosting its long-term growth prospects.
3. New High-Value Collaborations
Medium Probability
Securing additional multi-billion dollar partnerships with major pharmaceutical companies, similar to its Roche/Genentech deal, would provide significant funding, external validation, and access to broader markets, potentially driving a 50-75% stock price appreciation.
🐻 The Bear Case - Downside to US$3
1. Clinical Trial Failures
Medium Probability
Any significant setback or failure in the ongoing or upcoming clinical trials of its lead drug candidates could severely undermine investor confidence, leading to a potential 30-50% decline in share price.
2. Sustained High Cash Burn
High Probability
With negative operating cash flow, Recursion relies on capital raises. A prolonged period of high cash burn without significant progress could necessitate dilutive financing, negatively impacting shareholder value and pushing the stock towards its low target.
3. Intensifying Competition
Medium Probability
The rapidly evolving AI drug discovery landscape could see new entrants or more advanced technologies from competitors, diminishing Recursion's perceived advantage and making it harder to secure future partnerships or attract talent, hindering long-term growth.
🔮 Final thought: Is this a long term relationship?
Owning Recursion Pharmaceuticals for a decade hinges on the belief in the transformative power of AI in drug discovery and the company's ability to successfully translate its platform into approved therapies. The inherent risks of biotech, including trial failures and intense competition, are significant. However, if Recursion's technology proves superior in consistently bringing novel drugs to market, its early-mover advantage and strategic partnerships could create substantial long-term value, making it a compelling, albeit speculative, holding for investors with high risk tolerance.
📋 Appendix
Financial Performance
Metric
31 Dec 2025
31 Dec 2024
31 Dec 2023
Income Statement
Revenue
US$0.07B
US$0.06B
US$0.04B
Gross Profit
US$0.00B
US$0.01B
US$0.00B
Operating Income
US$-0.65B
US$-0.48B
US$-0.35B
Net Income
US$-0.64B
US$-0.46B
US$-0.33B
EPS (Diluted)
-1.44
-1.69
-1.58
Balance Sheet
Cash & Equivalents
US$0.74B
US$0.59B
US$0.39B
Total Assets
US$1.47B
US$1.45B
US$0.65B
Total Debt
US$0.08B
US$0.11B
US$0.05B
Shareholders' Equity
US$1.13B
US$1.03B
US$0.46B
Key Ratios
Gross Margin
4.4%
22.7%
2.9%
Operating Margin
-872.8%
-819.0%
-797.8%
Return on Equity
-57.01
-44.81
-70.79
Analyst Estimates
Metric
Annual (31 Dec 2026)
Annual (31 Dec 2027)
EPS Estimate
US$-0.99
US$-0.85
EPS Growth
+31.5%
+13.7%
Revenue Estimate
US$0.1B
US$0.1B
Revenue Growth
+9.9%
+73.0%
Number of Analysts
8
8
Valuation Ratios
| Metric | Value | Description |
|---|---|---|
| P/E Ratio (TTM) | -2.26 | The trailing twelve-month P/E ratio measures the current share price relative to the company's earnings per share over the past year. A negative value indicates the company is currently unprofitable. |
| Forward P/E | -3.82 | The forward P/E ratio is a measure of the price-to-earnings ratio using forecasted earnings for the next fiscal year, also negative for unprofitable companies. |
| Price/Sales (TTM) | 22.99 | The price-to-sales ratio compares the company's current stock price to its revenue per share over the past twelve months, often used for companies without positive earnings. |
| Price/Book (MRQ) | 1.52 | The price-to-book ratio compares a company's market value to its book value per share, indicating how much investors are willing to pay for each dollar of net assets. |
| EV/EBITDA | -1.86 | Enterprise Value to EBITDA is a valuation multiple that compares a company's total value (Enterprise Value) to its earnings before interest, taxes, depreciation, and amortization. A negative value indicates negative EBITDA, which is common for early-stage biotech companies. |
| Return on Equity (TTM) | -59.54 | Return on Equity measures the profitability of a company in relation to the equity of its shareholders, with a negative value indicating net losses relative to equity. |
| Operating Margin | -328.80 | Operating margin indicates how much profit a company makes on each dollar of sales after paying for variable costs of production, but before interest and taxes. A large negative margin signifies substantial operating losses. |